title: Cold atmospheric plasma for selectively ablating metastatic breast cancer cells.
abstract: Traditional breast cancer treatments such as surgery and radiotherapy contain many inherent limitations with regards to incomplete and nonselective tumor ablation. Cold atmospheric plasma (CAP) is an ionized gas where the ion temperature is close to room temperature. It contains electrons, charged particles, radicals, various excited molecules, UV photons and transient electric fields. These various compositional elements have the potential to either enhance and promote cellular activity, or disrupt and destroy them. In particular, based on this unique composition, CAP could offer a minimally-invasive surgical approach allowing for specific cancer cell or tumor tissue removal without influencing healthy cells. Thus, the objective of this research is to investigate a novel CAP-based therapy for selectively bone metastatic breast cancer treatment. For this purpose, human metastatic breast cancer (BrCa) cells and bone marrow derived human mesenchymal stem cells (MSCs) were separately treated with CAP, and behavioral changes were evaluated after 1, 3, and 5 days of culture. With different treatment times, different BrCa and MSC cell responses were observed. Our results showed that BrCa cells were more sensitive to these CAP treatments than MSCs under plasma dose conditions tested. It demonstrated that CAP can selectively ablate metastatic BrCa cells in vitro without damaging healthy MSCs at the metastatic bone site. In addition, our study showed that CAP treatment can significantly inhibit the migration and invasion of BrCa cells. The results suggest the great potential of CAP for breast cancer therapy.
authors.affiliation: Department of Mechanical and Aerospace Engineering, The George Washington University, Washington, District of Columbia, United States of America.
authors.forename: Mian
authors.initials: M
authors.lastname: Wang
authors.forename: Benjamin
authors.initials: B
authors.lastname: Holmes
authors.forename: Xiaoqian
authors.initials: X
authors.lastname: Cheng
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.forename: Michael
authors.initials: M
authors.lastname: Keidar
authors.forename: Lijie Grace
authors.initials: LG
authors.lastname: Zhang
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000187:drug effects*; D008856:Microscopy, Fluorescence; D009362:Neoplasm Metastasis; D058626:Plasma Gases / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D058626:Plasma Gases
references.citation: PLoS One. 2011;6(11):e28154
references.pmid: 22140530
references.citation: Cell Tissue Res. 2001 Sep;305(3):285-98
references.pmid: 11572082
references.citation: Small. 2010 Jul 19;6(14):1474-8
references.pmid: 20586057
references.citation: Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:6030-3
references.pmid: 19964148
references.citation: J Natl Compr Canc Netw. 2009 Oct;7 Suppl 7:S1-29; quiz S30
references.pmid: 19878635
references.citation: Int J Food Microbiol. 2003 Aug 15;85(1-2):151-8
references.pmid: 12810279
references.citation: Br J Cancer. 2011 Oct 25;105(9):1295-301
references.pmid: 21979421
references.citation: Int J Nanomedicine. 2012;7:2087-99
references.pmid: 22619545
references.citation: Sci Rep. 2012;2:636
references.pmid: 22957140
references.citation: Med Device Technol. 2006 Apr;17(3):26-8
references.pmid: 16736661
references.citation: Antimicrob Agents Chemother. 2011 Mar;55(3):1053-62
references.pmid: 21199923
references.citation: J Biomed Opt. 2008 Sep-Oct;13(5):054011
references.pmid: 19021391
references.citation: Ann Biomed Eng. 2011 Feb;39(2):674-87
references.pmid: 21046465
references.citation: PLoS One. 2011 Jan 21;6(1):e16270
references.pmid: 21283714